JP2014501784A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014501784A5 JP2014501784A5 JP2013548578A JP2013548578A JP2014501784A5 JP 2014501784 A5 JP2014501784 A5 JP 2014501784A5 JP 2013548578 A JP2013548578 A JP 2013548578A JP 2013548578 A JP2013548578 A JP 2013548578A JP 2014501784 A5 JP2014501784 A5 JP 2014501784A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- iron
- pharmaceutical composition
- oral dosage
- iron compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006186 oral dosage form Substances 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 150000002506 iron compounds Chemical class 0.000 claims 12
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 10
- 229920000642 polymer Polymers 0.000 claims 9
- 238000010521 absorption reaction Methods 0.000 claims 8
- 239000003623 enhancer Substances 0.000 claims 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 6
- 239000002552 dosage form Substances 0.000 claims 6
- -1 medium chain fatty acid salt Chemical class 0.000 claims 6
- 239000003826 tablet Substances 0.000 claims 6
- 239000000654 additive Substances 0.000 claims 5
- 230000000996 additive effect Effects 0.000 claims 5
- 230000003111 delayed effect Effects 0.000 claims 5
- 229910052742 iron Inorganic materials 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 4
- 239000002245 particle Substances 0.000 claims 4
- 239000007787 solid Substances 0.000 claims 4
- 239000013543 active substance Substances 0.000 claims 3
- 230000010437 erythropoiesis Effects 0.000 claims 3
- 239000000463 material Substances 0.000 claims 3
- 239000008188 pellet Substances 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 claims 2
- 206010022971 Iron Deficiencies Diseases 0.000 claims 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims 2
- 235000010323 ascorbic acid Nutrition 0.000 claims 2
- 239000011668 ascorbic acid Chemical class 0.000 claims 2
- 229960005070 ascorbic acid Drugs 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 238000013270 controlled release Methods 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 238000004090 dissolution Methods 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 150000002505 iron Chemical class 0.000 claims 2
- 239000008185 minitablet Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N Folic acid Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 1
- 102000001554 Hemoglobins Human genes 0.000 claims 1
- 108010054147 Hemoglobins Proteins 0.000 claims 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims 1
- 229930003270 Vitamin B Natural products 0.000 claims 1
- 229930003268 Vitamin C Natural products 0.000 claims 1
- 229930003316 Vitamin D Natural products 0.000 claims 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- 229940124532 absorption promoter Drugs 0.000 claims 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims 1
- 229960004050 aminobenzoic acid Drugs 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 235000001465 calcium Nutrition 0.000 claims 1
- 239000013522 chelant Substances 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- 238000007385 chemical modification Methods 0.000 claims 1
- 229960001231 choline Drugs 0.000 claims 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims 1
- 229910052804 chromium Inorganic materials 0.000 claims 1
- 239000011651 chromium Substances 0.000 claims 1
- 235000012721 chromium Nutrition 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 229910052802 copper Inorganic materials 0.000 claims 1
- 239000010949 copper Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000002702 enteric coating Substances 0.000 claims 1
- 238000009505 enteric coating Methods 0.000 claims 1
- 235000007144 ferric diphosphate Nutrition 0.000 claims 1
- 239000011706 ferric diphosphate Substances 0.000 claims 1
- CADNYOZXMIKYPR-UHFFFAOYSA-B ferric pyrophosphate Chemical compound [Fe+3].[Fe+3].[Fe+3].[Fe+3].[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O CADNYOZXMIKYPR-UHFFFAOYSA-B 0.000 claims 1
- 229940036404 ferric pyrophosphate Drugs 0.000 claims 1
- 235000003891 ferrous sulphate Nutrition 0.000 claims 1
- 239000011790 ferrous sulphate Substances 0.000 claims 1
- 229960000304 folic acid Drugs 0.000 claims 1
- 235000019152 folic acid Nutrition 0.000 claims 1
- 239000011724 folic acid Substances 0.000 claims 1
- 125000003929 folic acid group Chemical group 0.000 claims 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 1
- SXAWSYZURCZSDX-UHFFFAOYSA-B hydron;[hydroxy(oxido)phosphoryl] hydrogen phosphate;2-hydroxypropane-1,2,3-tricarboxylate;iron(3+);phosphonato phosphate Chemical compound [H+].[H+].[H+].[H+].[H+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].OP([O-])(=O)OP(O)([O-])=O.OP([O-])(=O)OP(O)([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O SXAWSYZURCZSDX-UHFFFAOYSA-B 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims 1
- 229960000367 inositol Drugs 0.000 claims 1
- 239000011630 iodine Substances 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 150000004698 iron complex Chemical class 0.000 claims 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims 1
- 239000013563 matrix tablet Substances 0.000 claims 1
- 150000004667 medium chain fatty acids Chemical class 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000002861 polymer material Substances 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims 1
- 239000011669 selenium Substances 0.000 claims 1
- 229910052711 selenium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 229960005480 sodium caprylate Drugs 0.000 claims 1
- BTURAGWYSMTVOW-UHFFFAOYSA-M sodium dodecanoate Chemical compound [Na+].CCCCCCCCCCCC([O-])=O BTURAGWYSMTVOW-UHFFFAOYSA-M 0.000 claims 1
- 229940082004 sodium laurate Drugs 0.000 claims 1
- BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical group [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- FIWQZURFGYXCEO-UHFFFAOYSA-M sodium;decanoate Chemical compound [Na+].CCCCCCCCCC([O-])=O FIWQZURFGYXCEO-UHFFFAOYSA-M 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 235000019155 vitamin A Nutrition 0.000 claims 1
- 239000011719 vitamin A Substances 0.000 claims 1
- 235000019156 vitamin B Nutrition 0.000 claims 1
- 239000011720 vitamin B Substances 0.000 claims 1
- 235000019154 vitamin C Nutrition 0.000 claims 1
- 239000011718 vitamin C Substances 0.000 claims 1
- 235000019166 vitamin D Nutrition 0.000 claims 1
- 239000011710 vitamin D Substances 0.000 claims 1
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 229940046009 vitamin E Drugs 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
- 229940045997 vitamin a Drugs 0.000 claims 1
- 229940046008 vitamin d Drugs 0.000 claims 1
- 239000011701 zinc Substances 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161430575P | 2011-01-07 | 2011-01-07 | |
| US61/430,575 | 2011-01-07 | ||
| PCT/US2012/020487 WO2012094598A2 (en) | 2011-01-07 | 2012-01-06 | Pharmaceutical compositions of iron for oral administration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014501784A JP2014501784A (ja) | 2014-01-23 |
| JP2014501784A5 true JP2014501784A5 (enExample) | 2015-02-26 |
Family
ID=46457982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013548578A Pending JP2014501784A (ja) | 2011-01-07 | 2012-01-06 | 経口投与用の鉄の医薬組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8802114B2 (enExample) |
| EP (1) | EP2661273A4 (enExample) |
| JP (1) | JP2014501784A (enExample) |
| KR (1) | KR20140026354A (enExample) |
| CN (1) | CN103476419A (enExample) |
| AU (1) | AU2012204213A1 (enExample) |
| BR (1) | BR112013017169A2 (enExample) |
| CA (1) | CA2819234A1 (enExample) |
| WO (1) | WO2012094598A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7658938B2 (en) | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
| CN102046192B (zh) * | 2008-05-07 | 2014-11-19 | 默里昂研究Ⅲ有限公司 | GnRH相关化合物的组合物及制备方法 |
| WO2010099255A1 (en) * | 2009-02-25 | 2010-09-02 | Merrion Research Iii Limited | Composition and drug delivery of bisphosphonates |
| US20110182985A1 (en) * | 2010-01-28 | 2011-07-28 | Coughlan David C | Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof |
| WO2011120033A1 (en) * | 2010-03-26 | 2011-09-29 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor xa inhibitors for oral administration |
| WO2011156563A2 (en) * | 2010-06-09 | 2011-12-15 | Emisphere Technologies, Inc. | Oral iron deficiency therapy |
| BR112015018549A8 (pt) * | 2013-02-01 | 2018-01-30 | Charak Llc | métodos de tratamento de deficiência de ferro |
| BR112016004231B1 (pt) * | 2013-08-28 | 2021-07-06 | Dsm Ip Assets B.V. | concentrado de caldo, processo para preparar o mesmo e composição alimentar pronta para comer compreendendo o referido concentrado de caldo |
| KR102339148B1 (ko) * | 2013-08-28 | 2021-12-15 | 디에스엠 아이피 어셋츠 비.브이. | 부용 농축물의 철 보충 |
| KR20160091918A (ko) * | 2013-11-05 | 2016-08-03 | 락웰 메디컬, 인코포레이티드 | 저반응성 환자에서 에리스로포이에틴 자극제의 용량을 감소시키는 방법 |
| US9492421B1 (en) * | 2013-11-14 | 2016-11-15 | Argent Development Group, Llc | Nutritional supplements for treatment of iron deficiency anemia |
| US10265384B2 (en) | 2015-01-29 | 2019-04-23 | Novo Nordisk A/S | Tablets comprising GLP-1 agonist and enteric coating |
| GB201515387D0 (en) | 2015-08-28 | 2015-10-14 | Amazentis Sa | Compositions |
| CN106344534B (zh) * | 2016-09-30 | 2019-07-19 | 广西科技大学 | 硫酸亚铁肠溶滴丸的制备方法 |
| DK3684344T3 (da) | 2017-10-25 | 2025-08-04 | Chiesi Farm Spa | Deferipron-tabletter med forsinket frigivelse og fremgangsmåder til anvendelse deraf |
| KR102084489B1 (ko) * | 2018-05-18 | 2020-03-04 | 강원대학교산학협력단 | 열용융압출법을 이용하여 제조된 철 나노콜로이드 분산체 및 이의 용도 |
| SG11202101625RA (en) * | 2018-09-05 | 2021-03-30 | Renapharma AB | An iron containing composition and use thereof |
| TWI717139B (zh) * | 2018-12-20 | 2021-01-21 | 普惠德生技股份有限公司 | 含有亞鐵胺基酸螯合物粒子的組合物用於製備治療或減緩自體免疫相關疾病的醫藥品的用途 |
| AU2020275505A1 (en) * | 2019-05-14 | 2021-12-23 | Nokha Trading Llp | Ferrous sulphate oral compositions |
| CN111714470B (zh) * | 2020-05-27 | 2022-04-08 | 天津瑞益瑞美生物技术有限公司 | 一种兽用肠溶乙二胺四乙酸铁钠预混剂及其制备方法 |
| MX2024001246A (es) * | 2021-08-16 | 2024-02-13 | Thermolife Int Llc | Composiciones de suplemento de hierro y metodos de uso de las mismas. |
| US12016850B2 (en) | 2022-04-11 | 2024-06-25 | Chiesi Farmaceutici S.P.A. | Modified release pharmaceutical formulations comprising deferiprone |
| US12016851B2 (en) | 2022-04-11 | 2024-06-25 | Chiesi Farmaceutici S.P.A. | Modified release pharmaceutical formulations comprising deferiprone |
Family Cites Families (149)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB953626A (en) | 1961-04-25 | 1964-03-25 | Meito Sangyo Kk | Enteric-coated tablets of dextran sulphate ester and method of preparation thereof |
| US4525339A (en) | 1982-10-15 | 1985-06-25 | Hoffmann-La Roche Inc. | Enteric coated oral dosage form |
| EP0147437A4 (en) | 1983-05-31 | 1987-03-05 | Choong-Gook Jang | DRY COMPOSITIONS WITH DIRECT COMPRESSION FOR DOSAGE FORMS WITH CONTROLLED ADMINISTRATION. |
| DE3331009A1 (de) | 1983-08-27 | 1985-03-14 | Basf Ag, 6700 Ludwigshafen | Verfahren zur erhoehung der enteralen resorbierbarkeit von heparin bzw. heparinoiden sowie das so erhaeltliche heparin- bzw. heparinoidpraeparat |
| US4590062A (en) | 1984-04-16 | 1986-05-20 | Tech Trade Corp. | Dry direct compression compositions for controlled release dosage forms |
| US4654155A (en) | 1985-03-29 | 1987-03-31 | Reynolds Metals Company | Microemulsion lubricant |
| US5288497A (en) | 1985-05-01 | 1994-02-22 | The University Of Utah | Compositions of oral dissolvable medicaments |
| US4764375A (en) | 1985-09-11 | 1988-08-16 | Kv Pharmaceutical Company | Sachet drug delivery system |
| US4789547A (en) | 1987-06-17 | 1988-12-06 | Warner-Lambert Company | Transdermal matrix system |
| IL87710A (en) | 1987-09-18 | 1992-06-21 | Ciba Geigy Ag | Covered floating retard form for controlled release in gastric juice |
| US5221734A (en) | 1987-10-01 | 1993-06-22 | Ciba-Geigy Corporation | Process for preparing a polypeptide growth factor for milk |
| GB2212396A (en) * | 1987-12-18 | 1989-07-26 | Procter & Gamble | Dietary supplement comprising calcium and delayed release coated iron |
| NZ228285A (en) | 1988-03-11 | 1991-08-27 | Teikoku Seiyaku Kk | Pharmaceutical composition comprising a polypeptide and adapted for intravaginal administration |
| US5169933A (en) | 1988-08-15 | 1992-12-08 | Neorx Corporation | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging |
| US5190748A (en) | 1988-11-22 | 1993-03-02 | Hoffmann-La Roche Inc. | Absorption enhancement of antibiotics |
| ZA898331B (en) | 1988-11-22 | 1990-07-25 | Hoffmann La Roche | Pharmaceutical compositions |
| IL92537A (en) | 1988-12-15 | 1994-04-12 | Riker Laboratories Inc | Topical preparations and dermal systems containing 1-isobutyl-H1-imidazo [C-4,5] quinoline-4-amine |
| GB2244015B (en) | 1990-03-14 | 1993-10-27 | Hadley Sections Limited | Tube and method of forming same |
| US5541155A (en) | 1994-04-22 | 1996-07-30 | Emisphere Technologies, Inc. | Acids and acid salts and their use in delivery systems |
| US5110606A (en) | 1990-11-13 | 1992-05-05 | Affinity Biotech, Inc. | Non-aqueous microemulsions for drug delivery |
| IT1245761B (it) | 1991-01-30 | 1994-10-14 | Alfa Wassermann Spa | Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale. |
| US5744450A (en) | 1991-03-14 | 1998-04-28 | The Salk Institute For Biological Studies | GnRH analogs |
| US5688761A (en) | 1991-04-19 | 1997-11-18 | Lds Technologies, Inc. | Convertible microemulsion formulations |
| WO1992018147A1 (en) | 1991-04-19 | 1992-10-29 | Affinity Biotech, Inc. | Convertible microemulsion formulations |
| CA2070061C (en) | 1991-06-07 | 2004-02-10 | Shigeyuki Takama | Physiologically active polypeptide-containing pharmaceutical composition |
| AU661080B2 (en) | 1991-11-22 | 1995-07-13 | Warner Chilcott Company, Llc | Risedronate delayed-release compositions |
| US5229130A (en) | 1991-12-20 | 1993-07-20 | Cygnus Therapeutics Systems | Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems |
| SE501389C2 (sv) | 1992-04-24 | 1995-01-30 | Leiras Oy | Farmaceutiskt preparat och förfarande för dess framställning |
| DE4317458A1 (de) | 1992-06-11 | 1993-12-16 | Bayer Ag | Verwendung von cyclischen Depsipeptiden mit 18 Ringatomen zur Bekämpfung von Endoparasiten, neue cyclische Depsipeptide mit 18 Ringatomen und Verfahren zu ihrer Herstellung |
| JP3190441B2 (ja) | 1992-07-20 | 2001-07-23 | エーザイ株式会社 | 塩酸アゼラスチンを含有する安定な製剤 |
| RU2068689C1 (ru) | 1992-09-24 | 1996-11-10 | Товарищество с ограниченной ответственностью "Лекрон" | Способ получения таблеток парацетамола |
| CA2148465C (en) | 1992-11-06 | 1999-11-02 | Minenobu Okayama | Oral pharmaceutical preparation releasable in the lower digestive tract |
| US5346701A (en) | 1993-02-22 | 1994-09-13 | Theratech, Inc. | Transmucosal delivery of macromolecular drugs |
| SE9302135D0 (sv) | 1993-06-18 | 1993-06-18 | Kabi Pharmacia Ab | New pharmaceutical composition |
| TW402506B (en) | 1993-06-24 | 2000-08-21 | Astra Ab | Therapeutic preparation for inhalation |
| ES2068762B1 (es) | 1993-07-21 | 1995-12-01 | Lipotec Sa | Un nuevo preparado farmaceutico para mejorar la biodisponibilidad de drogas de dificil absorcion y procedimiento para su obtencion. |
| CA2176927C (en) | 1993-11-17 | 2010-03-23 | Seang H. Yiv | Transparent liquid for encapsulated drug delivery |
| CA2182282C (en) | 1994-02-16 | 2006-04-18 | Jacqueline E. Briskin | Process for preparing fine particle pharmaceutical formulations |
| US5506207A (en) | 1994-03-18 | 1996-04-09 | The Salk Institute For Biological Studies | GNRH antagonists XIII |
| US5639469A (en) | 1994-06-15 | 1997-06-17 | Minnesota Mining And Manufacturing Company | Transmucosal delivery system |
| IL110024A (en) | 1994-06-15 | 1998-04-05 | Yissum Res Dev Co | Controlled release oral drug delivery system containing hydrogel- forming polymer |
| GB9414318D0 (en) | 1994-07-15 | 1994-09-07 | Dowelanco Ltd | Preparation of aqueous emulsions |
| AU713461B2 (en) | 1994-11-17 | 1999-12-02 | Toray Industries, Inc. | Preparation for percutaneous absorption |
| US6524557B1 (en) | 1994-12-22 | 2003-02-25 | Astrazeneca Ab | Aerosol formulations of peptides and proteins |
| US5650386A (en) | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
| EP0827402A2 (en) | 1995-05-17 | 1998-03-11 | Cedars-Sinai Medical Center | Compositions containing fatty acids for improving digestion and absorption in the small intestine |
| US6572879B1 (en) | 1995-06-07 | 2003-06-03 | Alza Corporation | Formulations for transdermal delivery of pergolide |
| US5631347A (en) | 1995-06-07 | 1997-05-20 | Eli Lilly And Company | Reducing gelation of a fatty acid-acylated protein |
| GB9516268D0 (en) | 1995-08-08 | 1995-10-11 | Danbiosyst Uk | Compositiion for enhanced uptake of polar drugs from the colon |
| US5626884A (en) * | 1995-08-18 | 1997-05-06 | Lockett; Curtis G. | Treatment of sickle cell disease |
| US5766620A (en) | 1995-10-23 | 1998-06-16 | Theratech, Inc. | Buccal delivery of glucagon-like insulinotropic peptides |
| US5807983A (en) | 1995-12-28 | 1998-09-15 | The Salk Institute For Biological Studies | GNRH antagonist betides |
| US6150522A (en) | 1996-05-20 | 2000-11-21 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| US6147088A (en) | 1996-05-20 | 2000-11-14 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| JP2000511532A (ja) | 1996-05-20 | 2000-09-05 | メルク エンド カンパニー インコーポレーテッド | 性腺刺激ホルモン放出ホルモンのアンタゴニスト |
| US5932547A (en) | 1996-07-03 | 1999-08-03 | Alza Corporation | Non-aqueous polar aprotic peptide formulations |
| US5916582A (en) | 1996-07-03 | 1999-06-29 | Alza Corporation | Aqueous formulations of peptides |
| GB9614235D0 (en) | 1996-07-06 | 1996-09-04 | Danbiosyst Uk | Composition for enhanced uptake of polar drugs from mucosal surfaces |
| JP2001503749A (ja) | 1996-10-30 | 2001-03-21 | セラテック・インコーポレーテッド | 透過促進剤としてのグリコール酸の脂肪酸エステル及びその塩 |
| US5821230A (en) | 1997-04-11 | 1998-10-13 | Ferring Bv | GnRH antagonist decapeptides |
| US5925730A (en) | 1997-04-11 | 1999-07-20 | Ferring Bv | GnRH antagonists |
| US6156772A (en) | 1997-06-05 | 2000-12-05 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| US5981550A (en) | 1997-06-05 | 1999-11-09 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| US6156767A (en) | 1997-06-05 | 2000-12-05 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| US6004984A (en) | 1997-06-05 | 1999-12-21 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| WO1999001579A1 (en) | 1997-07-01 | 1999-01-14 | Isis Pharmaceuticals, Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
| IL121268A0 (en) | 1997-07-09 | 1998-01-04 | Dpharm Ltd | Branched chain fatty acids their derivatives and use in the treatment of central nervous system disorders |
| IL121269A0 (en) | 1997-07-09 | 1998-01-04 | Dpharm Ltd | Compositions and methods for reversibly increasing permeability of biomembranes |
| SE9703691D0 (sv) | 1997-10-10 | 1997-10-10 | Astra Ab | Pharmaceutical compositions |
| US6017944A (en) | 1997-10-28 | 2000-01-25 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| CN1160079C (zh) | 1998-03-11 | 2004-08-04 | 格勒兰制药株式会社 | 发泡性肠溶制剂 |
| US6077847A (en) | 1998-04-02 | 2000-06-20 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| US5998432A (en) | 1998-04-02 | 1999-12-07 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| US6025366A (en) | 1998-04-02 | 2000-02-15 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| US6270804B1 (en) | 1998-04-03 | 2001-08-07 | Biovail Technologies Ltd. | Sachet formulations |
| GB2336311A (en) | 1998-04-15 | 1999-10-20 | Merck & Co Inc | Bisphosphonate Dosing Regimen |
| US6656922B2 (en) | 1998-05-28 | 2003-12-02 | Mediplex Corporation, Korea | Oral delivery of macromolecules |
| JP3853985B2 (ja) * | 1998-08-03 | 2006-12-06 | 有限会社 健康百二十才 | 鉄イオン含有殺菌液 |
| WO2000022909A2 (en) | 1998-10-19 | 2000-04-27 | Biotech Australia Pty. Limited | Systems for oral delivery |
| US8119159B2 (en) | 1999-02-22 | 2012-02-21 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
| CA2363123C (en) * | 1999-02-22 | 2011-09-06 | Kenneth Iain Cumming | Solid oral dosage form containing an enhancer |
| US20070148228A1 (en) | 1999-02-22 | 2007-06-28 | Merrion Research I Limited | Solid oral dosage form containing an enhancer |
| US7658938B2 (en) | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
| SE9901272D0 (sv) | 1999-04-09 | 1999-04-09 | Astra Ab | New improved formulation |
| JP2001081031A (ja) | 1999-08-30 | 2001-03-27 | Schering Ag | 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤 |
| CA2393682C (en) | 1999-12-08 | 2012-01-31 | Xcyte Therapies, Inc. | Depsipeptide and congeners thereof for use as immunosuppressants |
| US20010044427A1 (en) | 1999-12-20 | 2001-11-22 | Sidney Mazel | Pharmaceutical kit |
| US20020002140A1 (en) | 2000-01-14 | 2002-01-03 | Holick Michael F. | Novel bisphosphonates and uses thereof |
| JP2004517800A (ja) | 2000-04-07 | 2004-06-17 | ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム | 両性イオンリン脂質およびビスホスホネートを含む独特の組成物および胃腸毒性を低減化したビスホスフェートデリバリーシステムとしての該組成物の使用 |
| US6468559B1 (en) | 2000-04-28 | 2002-10-22 | Lipocine, Inc. | Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods |
| IT1318539B1 (it) | 2000-05-26 | 2003-08-27 | Italfarmaco Spa | Composizioni farmaceutiche a rilascio prolungato per lasomministrazione parenterale di sostanze idrofile biologicamente |
| CN1141974C (zh) | 2000-06-07 | 2004-03-17 | 张昊 | 结肠定位释放的口服生物制剂 |
| US8052987B2 (en) | 2000-06-20 | 2011-11-08 | Novartis Pharmaceuticals Corporation | Method of administering bisphosphonates |
| AU2002243231A1 (en) | 2000-11-21 | 2002-07-24 | Wake Forest University | Method of treating autoimmune diseases |
| GB0029111D0 (en) | 2000-11-29 | 2001-01-10 | Novartis Ag | Organic compounds |
| US6379960B1 (en) | 2000-12-06 | 2002-04-30 | Isis Pharmaceuticals, Inc. | Antisense modulation of damage-specific DNA binding protein 2, p48 expression |
| US20020103131A1 (en) | 2001-01-26 | 2002-08-01 | Jacobson Jill D. | Prevention of diabetes by administration of GnRH antagonists |
| EP1390048A2 (en) | 2001-02-16 | 2004-02-25 | Shimizu Pharmaceutical Co., Ltd. | Oral formulations containing mucopolysaccharide for small intestine delivery and their use in the treatment circulatory disorders |
| NZ527157A (en) | 2001-03-01 | 2005-04-29 | Emisphere Tech Inc | Compositions for delivering bisphosphonates |
| US20040157799A1 (en) | 2001-05-02 | 2004-08-12 | Seaman John J | Pharmaceutical uses of bisphosphonates |
| EP1390024A4 (en) | 2001-05-11 | 2010-02-17 | Merrion Res Iii Ltd | ISOSTEARIC ACID SALTS AS PERMEATION IMPROVERS |
| WO2003003999A2 (en) | 2001-07-02 | 2003-01-16 | Elan Corporation, Plc. | Delivery of a bioactive material |
| US20030031757A1 (en) * | 2001-08-03 | 2003-02-13 | Kraft Food Holdings, Inc. | Stable and bioavailable iron fortified beverages |
| US6716814B2 (en) * | 2001-08-16 | 2004-04-06 | Albion International, Inc. | Enhancing solubility of iron amino acid chelates and iron proteinates |
| US7098305B2 (en) | 2001-09-06 | 2006-08-29 | Ardana Bioscience Limited | Sustained release of microcrystalline peptide suspensions |
| DE10157628A1 (de) | 2001-11-26 | 2003-06-12 | Zentaris Ag | Injektionslösung eines LHRH-Antagonisten |
| US7214662B2 (en) | 2001-11-27 | 2007-05-08 | Zentaris Gmbh | Injectable solution of an LHRH antagonist |
| DE60231549D1 (de) | 2001-12-03 | 2009-04-23 | Dor Biopharma Inc | Stabilisierte umkehr-mizellen-zusammensetzungen und ihre verwendung |
| US20030139378A1 (en) | 2001-12-13 | 2003-07-24 | Daifotis Anastasia G. | Liquid bisphosphonate formulations for bone disorders |
| CN1606432A (zh) | 2001-12-19 | 2005-04-13 | 阿尔扎公司 | 用于增加亲水性大分子的口服生物利用度的制剂和剂型 |
| AU2003211474A1 (en) | 2002-02-28 | 2003-09-09 | Nipro Corporation | Stabilized albumin preparaions |
| US7148257B2 (en) | 2002-03-04 | 2006-12-12 | Merck Hdac Research, Llc | Methods of treating mesothelioma with suberoylanilide hydroxamic acid |
| KR20140021045A (ko) | 2002-05-10 | 2014-02-19 | 에프. 호프만-라 로슈 아게 | 골다공증 치료 및 예방용 비스포스폰산 |
| US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US20050080075A1 (en) | 2003-08-25 | 2005-04-14 | Nichols M. James | Formulations, conjugates, and combinations of drugs for the treatment of neoplasms |
| KR20060058134A (ko) | 2003-09-19 | 2006-05-29 | 화이자 프로덕츠 인코포레이티드 | 2-알킬리덴-19-노르-비타민 디 유도체 및비스포스포네이트의 조합을 포함하는 약학 조성물 및 방법 |
| WO2005041925A2 (en) * | 2003-10-31 | 2005-05-12 | Alza Corporation | Compositions and dosage forms for enhanced absorption |
| US8987322B2 (en) | 2003-11-04 | 2015-03-24 | Circ Pharma Research And Development Limited | Pharmaceutical formulations for carrier-mediated transport statins and uses thereof |
| DE10358525A1 (de) | 2003-12-13 | 2005-07-07 | Bayer Healthcare Ag | Endoparasitizide Mittel zur topischen Applikation |
| AR046773A1 (es) | 2003-12-23 | 2005-12-21 | Novartis Ag | Formulaciones farmaceuticas de bisfosfonatos |
| AU2003290345A1 (en) | 2003-12-24 | 2005-07-14 | Astrazeneca Ab | Pharmaceutical dissolution testing using a non-ionic surfactant |
| US7606313B2 (en) | 2004-01-15 | 2009-10-20 | Ittiam Systems (P) Ltd. | System, method, and apparatus for error concealment in coded video signals |
| WO2005072747A1 (ja) | 2004-02-02 | 2005-08-11 | Ono Pharmaceutical Co., Ltd. | 骨吸収抑制剤 |
| US20070219131A1 (en) | 2004-04-15 | 2007-09-20 | Ben-Sasson Shmuel A | Compositions capable of facilitating penetration across a biological barrier |
| WO2006097793A2 (en) | 2004-04-15 | 2006-09-21 | Chiasma, Ltd. | Compositions capable of facilitating penetration across a biological barrier |
| US20070212395A1 (en) | 2006-03-08 | 2007-09-13 | Allergan, Inc. | Ocular therapy using sirtuin-activating agents |
| BRPI0511530A (pt) | 2004-05-24 | 2008-01-02 | Procter & Gamble | formas de dosagem de bisfosfonatos |
| EP1778278B1 (en) | 2004-07-16 | 2014-05-21 | Oakwood Laboratories L.L.C. | Gonadotropin releasing hormone antagonists |
| CN103223160B (zh) | 2004-07-19 | 2015-02-18 | 比奥孔有限公司 | 胰岛素-低聚物共轭物,制剂及其用途 |
| EP1789434B1 (en) | 2004-08-31 | 2013-11-20 | Novo Nordisk A/S | Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins |
| EP1674082A1 (de) | 2004-12-22 | 2006-06-28 | Zentaris GmbH | Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel |
| EP1865928A1 (en) | 2005-03-17 | 2007-12-19 | Elan Pharma International Limited | Nanoparticulate biphosphonate compositions |
| TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| IL174387A0 (en) | 2005-03-31 | 2008-01-20 | Dexcel Pharma Technologies Ltd | A solid composition for intra-oral delivery of insulin |
| CA2606386C (en) * | 2005-04-29 | 2014-06-10 | Cubist Pharmaceuticals, Inc. | Therapeutic compositions |
| US20090060861A1 (en) | 2005-05-25 | 2009-03-05 | Novo Nordisk A/S | Stabilized Polypeptide Formulations |
| CA2612508A1 (en) | 2005-06-17 | 2006-12-28 | Dynamis Therapeutics, Inc. | Treatment of inflammatory conditions |
| US20070021378A1 (en) | 2005-07-22 | 2007-01-25 | The Regents Of The University Of California | Heparin compositions and selectin inhibition |
| US20070077313A1 (en) | 2005-10-04 | 2007-04-05 | U.S. Pharmaceutical Corporation | Toleration iron supplement compositions |
| WO2007117706A2 (en) | 2006-04-07 | 2007-10-18 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
| EP2040731A4 (en) | 2006-06-09 | 2010-05-19 | Merrion Res Iii Ltd | SOLID DOSAGE FORM FOR ORAL ADMINISTRATION CONTAINING AN ACTIVATOR |
| US20090004281A1 (en) | 2007-06-26 | 2009-01-01 | Biovail Laboratories International S.R.L. | Multiparticulate osmotic delivery system |
| CN101125132A (zh) | 2007-07-25 | 2008-02-20 | 司炳奎 | 口服胰岛素肠溶胶囊及其制备方法 |
| CN102046192B (zh) | 2008-05-07 | 2014-11-19 | 默里昂研究Ⅲ有限公司 | GnRH相关化合物的组合物及制备方法 |
| ES3058497T3 (en) | 2008-09-17 | 2026-03-11 | Amryt Endo Inc | Pharmaceutical compositions comprising polypeptides and related methods of delivery |
| WO2010099255A1 (en) | 2009-02-25 | 2010-09-02 | Merrion Research Iii Limited | Composition and drug delivery of bisphosphonates |
| US20110182985A1 (en) | 2010-01-28 | 2011-07-28 | Coughlan David C | Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof |
| WO2011120033A1 (en) | 2010-03-26 | 2011-09-29 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor xa inhibitors for oral administration |
| EP2651395A4 (en) | 2010-12-15 | 2014-05-07 | Merrion Res Iii Ltd | PHARMACEUTICAL COMPOSITIONS OF SELECTIVE FACTOR XA INHIBITORS FOR ORAL ADMINISTRATION |
-
2012
- 2012-01-06 WO PCT/US2012/020487 patent/WO2012094598A2/en not_active Ceased
- 2012-01-06 KR KR1020137017418A patent/KR20140026354A/ko not_active Withdrawn
- 2012-01-06 CA CA2819234A patent/CA2819234A1/en not_active Abandoned
- 2012-01-06 CN CN2012800046818A patent/CN103476419A/zh active Pending
- 2012-01-06 AU AU2012204213A patent/AU2012204213A1/en not_active Abandoned
- 2012-01-06 US US13/345,185 patent/US8802114B2/en not_active Expired - Fee Related
- 2012-01-06 BR BR112013017169A patent/BR112013017169A2/pt not_active IP Right Cessation
- 2012-01-06 JP JP2013548578A patent/JP2014501784A/ja active Pending
- 2012-01-06 EP EP12732499.4A patent/EP2661273A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6445648B2 (ja) | キレート化複合ミセルを有する薬物キャリア及びその応用 | |
| JP2012067115A5 (enExample) | ||
| JP2008525442A (ja) | 鉄を含む組成物 | |
| Theysohn et al. | Selective internal radiation therapy of hepatocellular carcinoma: potential hepatopulmonary shunt reduction after sorafenib administration | |
| KR101891357B1 (ko) | 양극성 트랜스 카로티노이드의 경구용 제형 | |
| JP2010270124A5 (enExample) | ||
| JP2019507797A5 (enExample) | ||
| CO6260019A2 (es) | Metodos para el tratamiento de desordenes gastrointestinales independientes de la ingesta de alimento | |
| JP2014528423A5 (enExample) | ||
| RU2014148239A (ru) | Фармацевтическая композиция, содержащая никотиновую кислоту и/или никотинамид, и/или триптофан, для положительного воздействия на кишечную микробиоту | |
| JP2009530398A5 (enExample) | ||
| JP2012519201A5 (enExample) | ||
| ES2895044T3 (es) | Suplemento de hierro | |
| HRP20151347T1 (hr) | Nova kombinacija | |
| JP2019526671A5 (enExample) | ||
| JP2019510834A5 (enExample) | ||
| JPS63145229A (ja) | ビタミンｂ６含有医薬組成物 | |
| Loghman-Adham | Safety of new phosphate binders for chronic renal failure | |
| EP3007680A1 (en) | Extended release nicotinamide formulation | |
| JPS59155312A (ja) | 新規薬理製剤 | |
| AU2016252864A1 (en) | Metal complexes with bisphosphonate or pyrophosphate useful as imaging agents | |
| JP6938534B2 (ja) | 癌及び腫瘍の治療または予防における使用のためのマルトール第二鉄組成物 | |
| CA3013795A1 (en) | Time release vitamins and minerals in edible oils | |
| Abir et al. | The role of arachidonic acid regulatory enzymes in colorectal disease | |
| CN106880639A (zh) | 阿司匹林和维生素c复方肠溶片及其制备方法 |